Historically, many locally advanced NSCLC trials have included patients with unresectable stage II disease. While those patients comprised only a few % of the study population, I think it is largely reasonable to extrapolate findings from stage III NSCLC patients to patients with unresectable stage ...

In this patient population where we do not have data to guide treatment decisions, S1933 is a potential option. This study targets stage II patients who are not surgical candidates and stage III patients with ECOG PS 2. Patients are treated with hypofractionated radiotherapy followed by atezolizumab...